Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSVpreF vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSVpreF is a bivalent, recombinant subunit vaccine developed to prevent respiratory syncytial virus (RSV) infection. It contains stabilized prefusion F protein antigens from both RSV-A and RSV-B subtypes. The prefusion F protein is a critical viral surface glycoprotein that mediates fusion of the virus with host cells; stabilizing it in the prefusion conformation elicits potent neutralizing antibodies. The primary mechanism of action is induction of an immune response against the prefusion F protein, providing protection against lower respiratory tract disease (LRTD) caused by RSV in adults and infants. In pregnant women, vaccination leads to transplacental transfer of protective antibodies to infants for up to six months after birth[1][5][7][8]. Developed by Pfizer, ABRYSVO (RSVpreF) is FDA-approved for use in older adults and pregnant women.
- Brand names
- Abrysvo
- Other names
- bivalent RSVpreF vaccinePfizer RSVpreF vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSVpreF vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSVpreF vaccine.